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Abstract Chronic N-methyl-D-aspartate receptor (NMDAR)
antagonist treatment can provide valuable neurochemical and
neuroanatomical models of experimental psychosis. One such
antagonist, ketamine, with its short half-time and well-
documented psychotomimetic action, has cognitive effects re-
sembling various aspects of schizophrenia-like symptoms. In
order to obtain insights into possible relationships between
Ca2+ homeostasis and schizophrenia-related symptoms, we
investigate the effects of chronic ketamine administration on
intracellular Ca2+ levels in various brain regions and on the
expression level of key members of the neuronal Ca2+-han-
dling system in rats. We show increased intracellular [Ca2+] in
all of the examined brain regions following ketamine treat-
ment but an altered cytosolic Ca2+ level correlated with
hyperlocomotor activity was only established for the cortex
and striatum. Our findings also suggest that an imbalance in
the expression between the calcium Bon^ and Boff^ systems
contributes to the deregulation of brain Ca2+ homeostasis in
our ketamine-induced model of experimental psychosis. Iden-
tification of the genes whose expression is affected by keta-
mine treatment indicates their involvement as putative etiolog-
ical factors in schizophrenia.
Keywords Calcium homeostasis . Ketamine . NMDA
receptor . Experimental psychosis . Rat
Introduction
Although the pathophysiology of schizophrenia has not yet
been elucidated, clinical findings have led to the hypothesis
that the hypofunction of N-methyl-D-aspartate receptors
(NMDAR) underlies the induction of psychotic symptoms
(Lajtha et al. 2009). This so-called Bglutamate hypothesis^
has developed because NMDAR non-competitive antago-
nists, such as ketamine, produce schizophrenia-like symptoms
in healthy humans (Krystal et al. 1994). In rodents, the admin-
istration of NMDAR blockers produces analogous behavioral
abnormalities including increased locomotion, ataxia, cogni-
tive defects and social withdrawal (Lajtha et al. 2009). Despite
mimicking a spectrum of psychotic symptoms, the simple
blockade of NMDAR cannot explain all accompanying de-
fects, which are likely to have a multifactorial origin. The idea
proposed by Jimerson et al. in 1979 (Jimerson et al. 1979) and
supported by further findings (Lidow 2003) that altered intra-
cellular Ca2+ signaling contributes to schizophrenia etiology
and has now returned to the mainstream of schizophrenia re-
search. According to this theory, disturbed Ca2+ homeostasis
and subsequent dysfunctions in Ca2+-regulated signal trans-
duction cause schizophrenic symptomology. Indeed, postmor-
tem studies have consistently reported structural and function-
al abnormalities in the prefrontal cortex, hippocampus and
cerebellum and dysregulation of the striatal dopaminergic sys-
tem in schizophrenia (Lajtha et al. 2009).
Calcium homeostasis in neural cells is maintained by items
in the Ca2+ signaling toolkit called Bon^ and Boff^ mecha-
nisms. The activation of Bon^mechanisms increases the intra-
cellular Ca2+ concentration ([Ca2+]c), whereas Boff^ systems
tend to restore the resting Ca2+ level. Most of the extracellular
Ca2+ enters the cell through voltage-dependent Ca2+ channels
and store-operated Ca2+ channels (SOCs). Voltage-dependent
Ca2+ channels encoded by the CACNA1A-S genes are key
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transducers of electrical excitability to intracellular Ca2+ tran-
sients, which, in turn, initiate neurotransmission by triggering
vesicular release (Stanley 1993). SOCs respond to endoplas-
mic reticulum (ER) store depletion and, together with STIM1
and ORAI1 proteins, participate in ER refilling via a store-
operated Ca2+ entry mechanism. Moreover, a few members of
canonical transient receptor potential channels (TRPC), which
are nonselective plasma membrane cation channels with a
preference for Ca2+ over Na+, are considered to be SOCs
(Smyth et al. 2010).
Ca2+ clearance mechanisms aimed at restoring the basal
Ca2+ level during the Boff^ phase include a network of
plasma-membrane-located Na+/Ca2+ exchangers (NCX1-3),
ATP-dependent Ca2+ pumps (PMCA1-4), sarco(endo)plasmic
reticulum Ca2+-ATPases (neuronal SERCA2-3) and
secretory-pathway Ca2+-ATPases (SPCA1-2) located in the
membrane of the Golgi apparatus. Furthermore, significant
amounts of cytosolic Ca2+ can also be accumulated by mito-
chondria. This Ca2+ uptake undertaken by the mitochondrial
calcium uniporter (MCU) shapes spatiotemporal Ca2+ signals
and might trigger cell death (Kirichok et al. 2004).
However, more recent studies have shown that chronic
NMDAR antagonist treatment can provide a valuable neuro-
chemical and neuroanatomical model of experimental psycho-
sis (Lajtha et al. 2009). Ketamine, because of its short half-
time and well-documented psychotomimetic action, has cog-
nitive effects resembling various aspects of schizophrenia-like
symptoms (Stefani and Moghaddam 2005; Neilla et al. 2010).
Therefore, in order to obtain insights into a possible relation-
ship between Ca2+ homeostasis and schizophrenia-related
symptoms, we investigate the effects of chronic ketamine ad-
ministration on the expression level of key players in the neu-
ronal Ca2+-handling system. Our findings suggest that imbal-
anced expression between calcium Bon^ and Boff^ systems
contributes to the deregulation of brain Ca2+ homeostasis in
a ketamine-induced model of experimental psychosis.
Materials and methods
Reagents
All reagents, if not separately mentioned, were pur-
chased from Sigma-Aldrich (Germany). The 5×HOT
FIREPol EvaGreen qPCR Mix was from Solis BioDyne
(Lithuania). The M-MLV reverse transcriptase, Trizol re-
agent and Fluo-4 Direct Calcium Assay Kit were from
Life Technologies (USA). We obtained the CytoTox-
ONE assay from Promega (USA). The ATPLite 1 step
Luminescence Assay System was purchased in Perkin-
Elmer (USA). Primers were synthesized in the Institute
of Biochemistry and Biophysics (Poland).
Animals and drug treatment
The 10– to 12-week-old male Wistar rats (in-house animal
facility, Medical University of Lodz) were group-housed in
laboratory cages and kept under a controlled temperature
(23±2 °C) with a 12-h light/dark cycle and with food and
water provided ad libitum. For 5 consecutive days, randomly
chosen rats (n=12) were injected intraperitoneally with keta-
mine (30 mg/kg) dissolved in physiological saline. Injections
of ketamine for 5 consecutive days were shown to induce the
behavioral and molecular changes related to schizophrenia-
like alterations (Becker et al. 2003). The control group
(n=12) was injected with saline only (0.5 ml/kg). All animal
experimentation was conducted in accordance with Directive
2010/63/EU of the European Parliament on the protection of
animals used for scientific purposes. All the procedures used
were also approved by the Institutional Animal Care and Use
Committee at Medical University of Lodz.
Behavioral testing
On day 5 and approximately 2 h after final injection, animals
were placed in the open field (100 cm×100 cm×40 cm) and
were allowed to explore the arena freely for 10 min. Then,
locomotor activity was continuouslymeasured over 20min by
using a webcam connected to the ANY-maze video tracking
system (Stoelting, USA). The stereotypic behavior was eval-
uated by counting the amount of turning, weaving and bob-
bing. Weaving and head bobbing were assessed by counting
the neck wave up and down and left and right. Turning was
measured by counting the number of turns around. The cumu-
lative stereotypy was determined for each animal and was
expressed as the sum of each of the scores over 20 min. Be-
havioral tests were performed between 10 a.m. and 3 p.m.
Brain sample preparation
Immediately after behavioral testing and no longer than
3 h following final ketamine administration, animals were
decapitated by using a guillotine. Brains were freshly dis-
sected and used immediately or were frozen for further
use. For Ca2+ measurements, brains were processed essen-
tially as described in Rothman (1984). In brief, pieces of
the cortex, hippocampus, cerebellum and striatum
(∼200 mg each) were dissociated in 0.1 % trypsin in buff-
er A (10 mM TRIS–HCl, 138 mM NaCl, 5 mM KCl,
4 mM NaHCO3, 0.3 mM Na2HPO4, 0.44 mM KH2PO4,
5 . 6 mM g l u c o s e , 0 . 5 mM p h e n y l m e t h a n e
sulfonylfluoride, pH 7.4). Following a 15-min incubation
at 37 °C, samples were suspended in 1 ml trypsin-free
buffer A and passed through a Pasteur pipette with a
flame-narrowed tip. Then, cells from particular areas were
centrifuged twice at 200g for 5 min. The pellets were
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suspended in buffer B (buffer A supplemented with 5 mM
CaCl2, 1 mM MgCl2) and used for experiments.
Viability assays
Following dissociation, cellular viability was assessed by
means of two independent assays. The CytoTox-ONE as-
say was used to measure lactate dehydrogenase (LDH) re-
leased into the extracellular medium. For this purpose,
100 μl cell suspension in buffer B (for composition, see
Brain sample preparation) was taken from the control and
ketamine-treated groups after 2, 4, 8 and 12 h of incubation
and was placed into 96-well plates. LDH activity was de-
termined according to the manufacturer’s protocol. Cells
lysed with 0.1 % Triton X-100 were used to estimate the
maximal LDH amount available for release (0 % viability).
A second method was applied to quantify the intracellular
ATP content by using the ATPLite 1 Step Luminescence
Assay System. Cells were directly plated into 96-well
plates and the luminescent signal was recorded at various
time intervals (2, 4, 8 and 12 h following plating) accord-
ing to the manual provided by the supplier. Luminescence
detected by a GloMax 20/20 luminometer (Promega) was
converted to ATP values based on a calibration curve and
was expressed as nanomoles per milligram of protein. The
protein concentration was quantified by using Bio-Rad
Protein Assay.
Calcium measurement
Cell suspension (100μl) obtained as in Brain sample preparation
was immediately transferred to 96-well plates. An equal volume
of 2× Fluo-4 Direct calcium reagent loading solution was added
to each well and plates were incubated at 37 °C for 1 h. Fluo-
rescence was measured by using a Victor X3 plate reader
(Perkin-Elmer) set for excitation at 488 nm and emission at
535 nm. The signal was calibrated by the addition of 10 μM
ionomycin to obtain Fmax and 10 mM EGTA to record Fmin.
Changes in Fluo-4 fluorescence were converted to absolute
[Ca2+]c according to the equation [Ca
2+]free=Kd ([F-Fmin]/
[Fmax-F]), where Kd=345 nM.
Gene expression
Total RNA from dissected brain regions such as the cortex,
cerebellum, hippocampus and striatum was extracted with
Trizol Reagent following the manufacturer’s instructions.
Single-stranded cDNA was synthesized from 1 μg total
RNAwith oligo(dT) primers in a 20-μl mixture by using M-
MLV Reverse Transcriptase. Real-time quantitative polymer-
ase chain reaction (qPCR) was carried out with the Abi Prism
7000 sequence detection system (Applied Biosystems) by
using the EvaGreen qPCRMix and results were analyzed with
accompanying software. Amplifications were generated over
15 min at 95 °C followed by 40 cycles at 95 °C for 15 s, 60 °C
for 30 s and 72 °C for 30 s. The same conditions were used for
all analyzed genes. A melting curve was performed to assess
the specificity of the primers listed in Table 1. Relative quan-
tification of gene expression was performed with the 2-ΔΔCt
method (Livak and Schmittgen 2001) by using the expression
o f t he Gapdh (D-g l y c e ra l d ehyde -3 -pho spha t e
dehydrogenase) housekeeping gene to normalize the data.
Statistical analysis
The data are shown as means±SEM. The number of animals
used in particular experiments is given below each figure. The
results were analyzed by using STATISTICA 8.0 (StatSoft).
The two-tailed unpaired Student’s t-test (or the Mann–Whit-
ney U Test) and one-way analysis of variance (or Kruskal-
Wallis test depending on the normality of data) were used
when appropriate. P<0.05 was considered as statistically sig-
nificant. Correlations were assessed by using Pearson’s corre-




Administration of subanesthetic doses of ketamine (30 mg/kg)
promoted behavioral alterations significantly different from
those observed in the saline-treated group. Ketamine-
injected rats exhibited continuous locomotion with a quick
gait. Statistical analysis revealed considerably higher locomo-
tor activity in this group, as reflected by the significant in-
crease in the total distance travelled (P=0.02; Fig. 1a), mobil-
ity time (P = 0.016; Fig. 1a’), average speed (P = 0.019;
Fig. 1a’’) and number of body rotations (P = 0.013;
Fig. 1a’’’). In addition, the use of ketamine produced severe
stereotyped movements. As shown in Fig. 1b, cumulative
turning (P=0.042; Fig. 1b), weaving (P=0.041; Fig. 1b’),
head bobbing counts (P=0.024; Fig. 1b’’) and cumulative
scored stereotypy (P=0.038; Fig. 1b’’’) were significantly
higher in drug-administered rats.
Effect of ketamine on cell viability
To avoid a potential influence of cell death on the ana-
lyzed biochemical changes, we first monitored the mortal-
ity of the cells isolated from brain areas by measuring the
intracellular ATP level and LDH release (Reifert et al.
2011). ATP content decreased in a time-dependent man-
ner, which became statistically significant in all analyzed
brain regions after 8 h (Fig. 2a). To confirm, we next
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measured the release of LDH that reflected the compro-
mised membrane integrity. The profile of kinetics and the
extent of LDH release were similar to the ATP loss
(Fig. 2b). This indicates that the dissociation procedure
used here did not disturb plasma membrane integrity,
which remained intact for at least 4 h.
Effect of ketamine on Ca2+ homeostasis
Within 4 h after isolation of cells from brain areas, we
measured [Ca2+]c with the Fluo-4 calcium indicator.
Brain-region-dependent elevations of [Ca2+]c in the
ketamine-injected group were detected in comparison
Table 1 Primers used in real-
time polymerase chain reaction
for amplification of target genes
Gene Primer sequences °C NCBI number
PMCA1 F: 5’-CCTGAGGTACCAGAGGCAATAAA-3’ 57,71 NM_053311.1
R: 5’-TGGGTGTAAAATACCGCATTTG-3’ 57,51
PMCA2 F: 5’-ACCGTGGTGCAGGCCTATGT-3’ 56,76 NM_012508.5
R: 5’-GGCAATGGCGTTGACCAGCA-3’ 57,95
PMCA3 F: 5’-AGGCCTGGCAGACAACACCA-3’ 57,58 NM_133288.1
R: 5’-TCCCACACCAGCTGCAGGAA-3’ 58,06
PMCA4 F: 5’-ACGCGGTGTATCAGCTCGGA-3’ 58,29 NM_0010058
R: 5’-AGTGCTGGCTGGGTGGTGAA-3’ 57,64 71.1
SERCA2 F: 5’-TCTGTCATTCGGGAGTGGGG-3’ 55,9 NM_001110139.2
R: 5’-GCCCACACAGCCAACGAAAG-3’ 55,9
SERCA3 F: 5’-CCACCAGGGACACACCCCCA-3’ 60,0 NM_012914.1
R: 5’-AATGCCCGCCCGAGAACAGC-3’ 57,9
SPCA1 F: 5’-CCAGTGTGGCCGTGGCTGAC-3’ 60,0 NM_131907.2
R: 5’-TCAGCCTGGAGAAGGCCTGCAA-3’ 58,6
SPCA2 F: 5’-CCCTTCGCCACTGTATCCAAT-3’ 54,4 NM_001291454.1
R: 5’-CTCTCGGTTGCTGTAACGTCAT-3’ 54,8
NCX1 F: 5’-CCCAAGCTTAATGGAGAGACCACCAAGAC-3’ 62,9 NM_001270779.1
R: 5’-CGCGGATCCTTGGAAGCTGGTCTGTCTCC-3’ 67,2
NCX2 F: 5’-CCCAAGCTTCAGACTGCAAGGAGGGTGTC-3’ 65,8 NM_078619.1
R: 5’-CGCGGATCCAATCACCAGCAATGAACCCG-3’ 68,7
NCX3 F: 5’-CCCAAGCTTCAGACTGCAAGGAGGGTGTC-3’ 65,7 NM_078620.2
R: 5’-CGCGGATCCAATCACCAGCAATGAACCCG-3’ 65,7
TRPC1 F: 5’-CACAGTGGGCTTGGCCGGAG-3’ 60,0 NM_053558.1
R: 5’-CCGCAAGCACGAGGCCAGTT-3’ 57,9
TRPC3 F: 5’-GGCACAAGGCGTCGCTGAGT-3’ 57,9 NM_021771.2
R: 5’-GAAGGCCCAAGGCCACGACC-3’ 60,0
TRPC6 F: 5’-GGGGACCTCGCTCGTCCGAA-3’ 60,0 NM_053559.1
R: 5’-CTGCCATGGTCTGCTGCCGT-3’ 57,9
CACNA1a F: 5’-GCCCGGAGCGCAGAGGATGTA-3’ 60,2 NM_012918.3
R: 5’-TGGCGGACAGGGATGGGGTT-3’ 57,9
CACNA1b F: 5’-CAGCCCCATGTCTGCTGCCAA-3’ 58,3 NM_147141.1
R: 5’-GCCGAGTTCTGCTGCGGTGA-3’ 57,9
CACNA1c F: 5’-GCATCTCCATCACCTTCTTC-3’ 51,8 NM_012517.2
R: 5’-CAAATACCTGCATCCCAATC-3’ 49,7
CACNA1d F: 5’-CTACAGGCGGGATTAAGGAC-3’ 53,8 NM_017298.1
R: 5’-GTATTGGTCTGCTGAAGGGA-3’ 51,8
CACNA1h F: 5’-CAGCGCCGGTGAGAGCTTCC-3’ 60,0 NM_153814.1
R: 5’-TGGGACCGGCTGTTCCTCGT-3’ 57,9
STIM1 F: 5’-TGCGCTCGTCTTGCCCTGTG-3’ 57,9 NM_001108496.2
R: 5’-TGCGGACGGCCTCAAAGCTG-3’ 57,9
ORAI1 F: 5’-CACCGTCATCGGGACGCTGC-3’ 60,0 NM_001013982.1
R: 5’-CCGGTTCGGTGGGTGGCTTG-3’ 60,0
MCU F: 5’-AGTACGGTTGTCCCTCTGATG-3’ 56,7 NM_001106398.1
R: 5’-AGTGGTCCTCTTCTCCGCTTTC-3’ 56,7
GAPDH F: 5’-GGTTACCAGGGCTGCCTTCT-3’ 55,9 NG_028301.1
R: 5’-CTTCCCATTCTCAGCCTTGACT-3^ 54,8
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with control rats (Fig. 3). In the ketamine-treated rats, a
definite increase by ∼80 nM (P= 0.0001) was observed in
cells isolated from the striatum, followed by a change in
cerebellar cells by ∼40 nM (P = 0.004). The resting
[Ca2+]c in the cortical and hippocampal cells was higher
by ∼20 nM (P= 0.023, P= 0.042, respectively). In addi-
tion, a positive correlation was found between the loco-
motor activity in the rats and the increased calcium level
Fig. 1 Behavioral evaluation of saline and ketamine injected rats. a-a’’’
Locomotor activity. b-b’’’ Stereotypy. Animal behavior was scored by the
ANY-maze video tracking system. Tests were started 2 h after the last
ketaamine injection and rats were continuously monitored over 20 min.
Statistical differences between saline and ketamine-treated rats are indi-
cated by *P< 0.05; control group n= 12, tested group n = 12
Fig. 2 Viability of isolated brain
cells. The time course of cell
death was assessed by
determination of the intracellular
ATP level (a) and lactate
dehydrogenase (LDH) activity
(b). The ATP level at time 0 was
taken as 100 % of live cells. For
the LDH assay, % cytoxicity was
calculated by using the formula
(experimental LDH activity)/
(maximum LDH activity).
Maximum LDH release was
achieved by lysing cells with
0.1 % Triton X-100. Statistical
differences vs. time 0 are
indicated by *P< 0.05. control
group (left) n= 7; ketamine-
treated group (+ket) n= 7
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in the cortex cells (r= 0.705, P= 0.01; Fig. 4a) and the
striatum cells (r = 0.864, P = 0.001; Fig. 4b) but not in
the hippocampus cells (r=−0.33, P= 0.29; Fig. 4c) or in
the cerebellum cells (r=−0.21, P= 0.5; Fig. 4d).
Analysis of gene expression in ketamine-treated rats
Since [Ca2+]c was altered in ketamine-treated rats, we next an-
alyzed the transcripts levels of selected elements of Ca2+-han-
dling systems, including: voltage-dependent Ca2+ channels
(CACNA1a, CACNA1b, CACNA1c, CACNA1d,
CACNA1h), calcium pumps (PMCA1, PMCA2, PMCA3,
PMCA4, SERCA2, SERCA3, SPCA1, SPCA2), exchangers
(NCX1, NCX2, NCX3), participants in the store-operated
Ca2+ entry mechanism (TRPC1, TRPC3, TRPC6, ORAI1,
STIM1) and the MCU.
Cortex
Among the calcium Bon^ mechanisms, a pronounced
increase in the expression level was detected for
CACNA1c (P = 0 .042) and ORAI1 (P = 0 .047 ;
Fig. 5a). At the same time, the expression of another
member of the store-operated Ca2+ entry mechanism,
namely TRPC1, was decreased (P = 0.040). Within the
calcium removal systems, the greatest up-regulation in
response to ketamine was seen for MCU (P = 0.029),
PMCA4 (P = 0.0019) and SPCA1 (P = 0.025), whereas
Fig. 3 Measurements of
intracellular Ca2+ ([Ca2+]c) in
isolated brain cells. The resting
calcium level in ketamine-treated
or saline-treated brain cells was
determined fluorometrically by
using the Fluo-4 calcium indica-
tor. Statistical differences, tested
by the Mann–Whitney U test, be-
tween saline-treated (n= 12) and
ketamine-treated (n = 12) rats are
indicated by *P< 0.05
Fig. 4 Correlations between
resting [Ca2+]c and locomotor
activity (average speed) in
ketamine-injected rats. The line
on the graphs represents the re-
gressive line. Correlations
assessed for selected brain areas:
cortex (r= 0.705, P= 0.01, a),
striatum (r= 0.864, P= 0.001, b),
hippocampus (r=−0.33,
P= 0.29, c), cerebellum
(r =−0.21, P= 0.5, d). n= 12
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the expression of PMCA2 (P = 0.041) and SERCA3
(P = 0.045) was reduced (Fig. 5b). Additionally, the
down-regulation of the NCX3 isoform was observed
(P = 0.017).
Cerebellum
The most prominent up-regulation within the Bon^ systems was
detected for CACNA1h (P=0.0075) and a slight but statistically
significant increase was seen for CACNA1d (P=0.013), where-
as ketamine administration caused a decline in the CACNA1b
mRNA level (P=0.0069) by ∼60 % (Fig. 6a). A strong reduc-
tion of STIM expression level was observed (P=0.0046).More-
over, the cerebellum Boff^ systems showed an enhanced expres-
sion of PMCA1 (P=0.040), SERCA3 (P=0.015), and NCX1
(P=0.045) in response to ketamine but a reduction of nearly
80 % in mRNA level for PMCA3 (P= 0.047) and MCU
(P=0.035) occurred (Fig. 6b).
Hippocampus
Pronounced changes in mRNA level were observed for
both calcium Bon^ and Boff^ systems in the hippocam-
pus (Fig. 7a, b). Administration of the drug tended to
decrease the expression of CACNA1b (P = 0.038),
TRPC1 (P = 0.043), PMCA3 (P = 0.039) and MCU
(P= 0.018), the last two actively participating in Ca2+
clearance. The greatest increase in response to ketamine
was found for NCX3 mRNA (P = 0.013; Fig. 7b). In
addition, ketamine up-regulated CACNA1d (P = 0.015)
and SERCA3 (P= 0.038).
Fig. 5 Ketamine-induced changes in the expression of the participants in
the Ca2+-handling system in the cortex. The gene expression level for the
Bon^ (a) and Boff^ (b) systems was assessed by the real-time polymerase
chain reaction (PCR). The results are presented as relative units obtained
after normalization to the D-glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) reference gene. The expression level of each gene in control
samples (saline-injected rats) was taken as 1 (dotted line). Statistical dif-
ferences between saline-treated and ketamine-treated rats are indicated,
*P< 0.05. n= 12
Fig. 6 Ketamine-induced changes in the expression of the participants in
the Ca2+-handling system in the cerebellum. The gene expression level
for the Bon^ (a) and Boff^ (b) systems was assessed by real-time PCR.
The results are presented as relative units obtained after normalization to
the Gapdh reference gene. The expression level of the target gene in
control samples (saline-injected rats) was taken as 1 (dotted line). Statis-
tical differences between saline-treated and ketamine-treated rats are in-
dicated, *P< 0.05. n= 12
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Striatum
In the striatum, ketamine induced the most intensive
changes in the expression pattern of the Ca2+ homeostasis
participants (Fig. 8a). This was manifested by the altered
expression of 13 out of 22 examined genes. The expression
of genes encoding calcium Bon^ elements were mostly
down-regulated. Indeed, we detected lowered mRNA
levels for TRPC6 (P= 0.0038), CACNA1b (P = 0.0082),
CACNA1c (P = 0.016) and CACNA1d (P = 0.040). The
only exception was TRPC1, whose expression increased
by nearly 70 % (P= 0.040). The expression of a member
of the store-operated Ca2+ entry mechanism, namely
STIM1, was reduced (P= 0.047). Some of the most pro-
nounced changes ascribed to ketamine treatment were
found in the calcium Boff^ systems including a substantial
up-regulation of PMCA1 (P = 0.042), MCU (P = 0.032),
and SERCA3 (P= 0.043) genes, but a decline in PMCA3
(P= 0.0004), PMCA4 (P= 0.026), SPCA2 (P= 0.038) and
NCX2 (P= 0.028) mRNA level was detected (Fig. 8b).
Analysis of correlation between Ca2+-handling system
transcripts level and intracellular [Ca2+]c
To verify the potential relationship between increased [Ca2+]c
and the changes in the expression of the members of the
calcium-handling systems, we performed a correlation analy-
sis. A significant negative correlation was revealed in the cor-
tex for PMCA2 (r =−0.64, P = 0.047; Fig. 9a), PMCA4
(r = −0.73, P = 0.023; Fig. 9b) and SERCA3 (r = −0.96,
P=0.036; Fig. 9c) and a positive correlation was observed for
CACNA1c (r=0.77, P=0.04; Fig. 9d). In the cerebellum, a
negative correlation was found for PMCA1 (r = −0.65,
P=0.043; Fig. 9e), PMCA3 (r=−0.71, P=0.048; Fig. 9f) and
CACNA1d (r=0.80, P=0.049; Fig. 9g). Moreover, significant
Fig. 7 Ketamine-induced changes in the expression of the participants in
the Ca2+-handling system in the hippocampus. The gene expression level
for the Bon^ (a) and Boff^ (b) systems was assessed by real-time PCR.
The results are presented as relative units obtained after normalization to
the Gapdh reference gene. The expression level of the target gene in
control samples (saline-injected rats) was taken as 1 (dotted line). Statis-
tical differences between saline-treated and ketamine-treated rats are in-
dicated, *P< 0.05. n= 12
Fig. 8 Ketamine-induced changes in the expression of the participants in
the Ca2+-handling system in the striatum. The gene expression level for
the Bon^ (a) and Boff^ (b) systems was assessed by real-time PCR. The
results are presented as relative units obtained after normalization to the
Gapdh reference gene. The expression level of the target gene in control
samples (saline-injected rats) was taken as 1 (dotted line). Statistical dif-
ferences between saline-treated and ketamine-treated rats are indicated,
*P< 0.05. n= 12
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negative correlations were detected for PMCA3 (r=−0.75,
P=0.032; Fig. 9h), SERCA3 (r=−0.72, P=0.017; Fig. 9i) and
NCX3 (r=−0.88, p=0.031; Fig. 9j) in the hippocampus. Finally,
striatal transcript levels showed a negative correlation with
[Ca2+]c only for PMCA1 (r=−0.66,P=0.034; Fig. 9k), PMCA3
(r = −0.75, P = 0.016; Fig. 9l) and SERCA3 (r = −0.78,
P=0.026; Fig. 9m).
Discussion
Assuming that schizophrenia is a disease of calcium signaling,
the essential question to be asked is whether the up-regulation
or down-regulation of Ca2+-dependent cellular transmission
reveals a central molecular pathology. By using ketamine to
mimic schizophrenic symptoms in rats, we have shown in-
creased [Ca2+]c in all of the examined brain regions; however,
an altered cytosolic Ca2+ level is correlated with
hyperlocomotor activity only for the cortex and striatum.
The phenomenon of calcium homeostasis dysregulation can
be partially deduced from the ketamine-induced model of
schizophrenia. Namely, a reduction of NMDAR drive and a
concomitant decrease in Ca2+ flow result in the compensatory
down-regulation of Ca2+ sequestering proteins (Lidow 2003).
Blockade of NMDAR on gamma amino-butyric acid
(GABA)-ergic interneurons attenuates GABA release and abol-
ishes the inhibition of major excitatory pathways. One of the
possible consequences is a stimulation of Ca2+ entry through
glutamate-independent pathways and Ca2+ mobilization from
internal stores (Lidow 2003). Therefore, the overall effect of
NMDAR blockade is a prolongation of calcium dynamics and
a [Ca2+]c increase in a large population of neurons. This increase
can, in turn, inhibit NMDAR causing the dopamine D2
receptor-dependent potentiation of the ecytosolic calcium signal.
Fig. 9 Correlations between expression of the participants of the
calcium-handling systems and [Ca2+]c in ketamine-treated rats. The
graphs present the basal calcium concentration plotted as a function of
the expression level for each gene. Only relevant correlations are shown.
The line on the graph represents the regressive line. a–d Cortex. e–g
Cerebellum. h–j Hippocampus. k–m Striatum. n= 12
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The dopamine system is known to interact closely with Ca2+
signaling and both phasic dopamine release and the activity of
D2 receptors are dependent on the Ca2+ influx or Ca2+ release
from internal stores (Lidow 2003). The connection between an
abnormally elevated Ca2+ level and schizophrenia-like symp-
toms suggested in our study is additionally highlighted by recent
findings showing the ketamine-induced potentiation of dopa-
mine release and the reduction of GABA secretion from rat
striatum (Grasshoff et al. 2005; Meyer and Louilot 2012). This
finding agrees with the original dopamine hyperactivity hypoth-
esis of schizophrenia, which is further supported by several
studies showing the increased density of the striatal dopamine
D2 receptor (Lajtha et al. 2009; Lidow 2003).
Based on the well-established model of ketamine-induced
experimental psychoses, we demonstrated a correlation be-
tween altered calcium signaling in the cortex and striatum
and the generation of behavioral abnormalities. The prefrontal
cortex stands out as one of the main regions affected in schizo-
phrenia and the postnatal inactivation of this structure in rats
promotes behavioral alterations similar to ketamine-evoked
psychotic symptoms (Usun et al. 2013). Usun et al. (2013)
also found a ketamine-induced potentiation of striatal dopa-
mine release in adult rats following the postnatal blockade of
the prefrontal cortex. Dysfunctional interaction between cor-
tical and striatal dopamine systems is strongly suggested to
underlie the impaired motor function observed in our study. In
agreement with the above, we propose that ketamine alters
neural Ca2+ homeostasis by blocking NMDAR located on
GABAergic neurons in the striatum and prefrontal cortex; this
might influence Ca2+-dependent dopamine release resulting in
increased neural activity. Among GABAergic neurons, pre-
frontal cortical parvalbumin interneurons seem to be highly
sensitive to NMDA antagonists. Chronic exposure to keta-
mine leads to a reduction of GAD67 and parvalbumin expres-
sion in parallel with the activation of NADPH oxidase and
superoxide accumulation. Blocking of NADPH oxidase
prevented these actions, a finding that indicates this enzyme
as a source of parvalbumin interneuron vulnerability. There-
fore, psychotomimetic effects generated by NMDAR antago-
nists can be mediated, at least in part, by oxidative stress
produced by NADPH oxidase (Behrens et al. 2007; Zhang
et al. 2008). Additionally, chronic stress and subsequent dys-
regulation of calcium homeostasis have been shown to under-
lie the loss of parvalbumin-immunoreactive cells, an event
that is thought to impair GABAergic network function. The
physiological consequence of this deficit is the altered rhyth-
mic oscillations commonly observed in schizophrenic patients
(Hu et al. 2010; Filipović et al. 2013).
So far, most of the reports have focused on the relationship
between defective postsynaptic glutamatergic neurotransmis-
sion and schizophrenia-related symptoms. However, a grow-
ing body of evidence has also revealed presynaptic gluta-
matergic alterations, particularly connected with proteins
involved in synaptic vesicles fusion and exocytosis (Oni-
Orisan et al. 2008; Granseth et al. 2015). These reports strong-
ly indicate that the expression of vesicular glutamate trans-
porters VGLUT1 and 2 is changed in schizophrenia. Because
VGLUTs contribute to the machinery that facilitates glutamate
release, the down-regulation of transporter expression is ex-
pected to alter glutamate neurotransmission and synaptic ac-
tivity; indeed, gene-specific decreases in VGLUT mRNA
have been suggested in schizophrenia (Eastwood and
Harrison 2005). The importance of VGLUTs is further sup-
ported by studies with full knock-out mouse models.
VGLUT1 full knock-out mice die after weaning, as do
VGLUT2-deficient animals, which die immediately after
birth. Interestingly, mice with conditional VGLUT knock-
out showed hyperactivity, impaired social behaviors and cog-
nitive deficiency and displayed prepulse inhibition and, there-
fore, can be considered as a hypoglutamate model of
schizophrenia-like symptoms (Wallén-Mackenzie et al.
2010; Inta et al. 2012).
Also of interest, among the analyzed genes encoding calcium-
handling factors, we found only a few whose expression is cor-
related with increased [Ca2+]c. In order to avoid an exaggerated
analysis, we decided to limit our discussion of the potential effect
of ketamine on brain calcium homeostasis only to these genes. In
the cerebellum, hippocampus and striatum, ketamine administra-
tion leads to a down-regulation of PMCA3. This PMCA isoform
and PMCA2, whose expression is reduced in the cortex, are the
fastest PMCA isoforms and their presence is thought to sensitize
neuronal cells even to subtle changes in [Ca2+]c. Although the
data regarding specific PMCA3 function are scarce, several stud-
ies of neuronal cultures have shown that the reduced expression
of either PMCA2 or PMCA3 decreases Ca2+-clearing potency
making cells unable to maintain Ca2+ homeostasis (Fernandes et
al. 2007; Boczek et al. 2012). A slower return of Ca2+ transient to
the baseline and the compromised ability to oppose the influx of
calcium through the plasma membrane capacitive channels have
recently been attributed to dysfunctional PMCA3 (Zanni et al.
2012). In addition to affecting calcium clearance, decreased
levels of PMCA2 have also been associated with neuronal pa-
thology and a reduced number of motor neurons has been re-
vealed in PMCA2-deficient mice (Kurnellas et al. 2005). There-
fore, the lowered expression of PMCA2 or PMCA3 observed in
our study might form the basis of the inability to maintain calci-
um homeostasis following ketamine administration. This, in
turn, might contribute to the ketamine-induced neuronal death
observed in primates or even to the neuronal loss reported in
schizophrenic patients (Lajtha et al. 2009).
Increased expression of SERCA3 in the cortex, hippocam-
pus and striatum was correlated with a higher [Ca2+]c level in
these brain structures, suggesting a compensatory change by
sequestration of calcium to intracellular compartments. How-
ever, the changes in the Ca2+ content in the internal stores
depend upon the balance between the activity of SERCA
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pumps and Ca2+ leakage or release back into the cytosol. A
massive calcium efflux from the ER is not the reason for the
increased [Ca2+]c in ketamine-treated brains observed in our
study, as ketamine has been shown to decrease the release of
internally stored Ca2+ (Xiang et al. 2008). Therefore, the
higher SERCA3 expression might indicate the more efficient
packing of Ca2+ into the lumen of the ER aimed at reducing
the abnormally high cytosolic Ca2+ level. A similar reason can
be suggested for the up-regulation of PMCA1 in the striatum
and cerebellum, PMCA4 in the cortex and NCX3 in the hip-
pocampus. The beneficial role of PMCA and SERCA overex-
pression on the reduction and increase in the ER [Ca2+] level,
respectively, has previously been demonstrated in vivo (Brini et
al. 2000). Additionally, the compensatory up-regulation of
PMCA4 has been revealed in the anterior temporal lobes in
schizophrenic patients (Martins-de-Souza et al. 2009).
Calcium signaling through CACNA1 has been implicated
in several brain disorders and the CACNA1c variant has been
associated with schizophrenia (Lajtha et al. 2009). This has
been confirmed by recent genome-wide association studies
showing CACNA1c as a susceptibility gene for schizophrenia
in the worldwide population (Hamshere et al. 2013; Ripke et
al. 2013; Zheng et al. 2014). Despite these findings, data re-
garding the clinical effectiveness of calcium channel blockers
in schizophrenia treatment are scarce. So far, several reports
have only demonstrated the efficient use of verapamil, diltia-
zem, nifedipine and nimodipine as an adjunct therapy, allevi-
ating side effects such as tardive dyskinesia caused by neuro-
leptic drugs (Hollister and Trevino 1999; Essali et al. 2011). In
our study, an increased expression of subunits 1c and 1d (L-
type VDDCs) was observed in the cortex and cerebellum,
respectively but this might have a rather minor contribution
to the overall dysregulation of calcium homeostasis, possibly
because ketamine has been shown to inhibit the L-type depen-
dent Ca2+ current (Yamakage et al. 1995). Instead, we assume
that it might affect the proper function of numerous neurolog-
ical circuits, since L-type voltage-dependent Ca2+ channels
have been found to be engaged in mesolimbic-mediated be-
haviors and in the hippocampal formation of spatial memory
in rodents (Bhat et al. 2012).
In conclusion, we have shown that the inability to maintain
brain Ca2+ homeostasis in ketamine-treated rats might be caused
by an imbalanced expression between the calcium Bon^ and
Boff^ mechanisms. The key changes correlating with higher
[Ca2+]c involve the dysfunctional expression of the calcium ex-
truding systems, with a prevalence of PMCA2 and PMCA3.
Although various rescue mechanisms, i.e., the increased expres-
sion of constitutive PMCA isoforms or SERCA pumps, are
activated in discrete brain regions, a finding possibly related to
their functional specificity, they are still inefficient with regard to
the restoration of the balance of calcium ions. Consecutively, an
abnormal calcium signal can be linked with behavioral abnor-
malities; such a correlation has been revealed here for the cortex
and striatum. The identification of genes whose expression is
affected by ketamine treatment, in conjunction with the changes
reported in schizophrenia, indicate their involvement as putative
etiological factors of this disease.
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